NCT00005576View on ClinicalTrials.gov

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

March 31, 2002

Conditions
Disseminated NeuroblastomaRecurrent NeuroblastomaRegional Neuroblastoma
Interventions
BIOLOGICAL

monoclonal antibody Ch14.18

Given IV

DRUG

isotretinoin

Given orally

BIOLOGICAL

aldesleukin

Given IV

BIOLOGICAL

sargramostim

Given IV

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005576 - Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma | Biotech Hunter | Biotech Hunter